PRIME Designation Follows Recent FDA Regenerative Medicine Advanced Therapy Designation, Continues Regulatory Momentum for RTx-015

Funding provides significant capital to support late-stage clinical development and commercial readiness for lead program RTx-015 in Retinitis Pigmentosa, and clinical studies for RTx-021 in Stargardt Disease and Geographic Atrophy

BERKELEY, Calif. – April 1, 2026 – Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company pioneering optogenetic therapies for those living with retinal degenerative diseases, today announced that